366 related articles for article (PubMed ID: 27083895)
21. Tumefactive Demyelinating Lesions and Pregnancy.
Plantone D; Piantadosi C; Ruggieri S; Anelli V; Koudriavtseva T
Neurol India; 2019; 67(6):1519-1521. PubMed ID: 31857550
[TBL] [Abstract][Full Text] [Related]
22. Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.
Kiriyama T; Kataoka H; Taoka T; Tonomura Y; Terashima M; Morikawa M; Tanizawa E; Kawahara M; Furiya Y; Sugie K; Kichikawa K; Ueno S
J Neuroimaging; 2011 Apr; 21(2):e69-77. PubMed ID: 20572907
[TBL] [Abstract][Full Text] [Related]
23. Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló's concentric sclerosis.
Hardy TA; Tobin WO; Lucchinetti CF
Mult Scler; 2016 Jul; 22(8):986-92. PubMed ID: 27037180
[TBL] [Abstract][Full Text] [Related]
24. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
[TBL] [Abstract][Full Text] [Related]
25. Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.
Kobayashi M; Shimizu Y; Shibata N; Uchiyama S
J Neurol; 2014 Oct; 261(10):1902-10. PubMed ID: 25034274
[TBL] [Abstract][Full Text] [Related]
26. Risk of multiple sclerosis after a first demyelinating syndrome in an Australian Paediatric cohort: clinical, radiological features and application of the McDonald 2010 MRI criteria.
Tantsis EM; Prelog K; Brilot F; Dale RC
Mult Scler; 2013 Nov; 19(13):1749-59. PubMed ID: 23579092
[TBL] [Abstract][Full Text] [Related]
27. Tumefactive demyelinating lesion: experience with two unusual patients.
Sinha MK; Garg RK; Bhatt ML; Chandra A
J Postgrad Med; 2010; 56(2):146-9. PubMed ID: 20622396
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in Tumefactive demyelinating lesions: A retrospective study.
Plowman RS; Varma H
J Neurol Sci; 2021 Sep; 428():117591. PubMed ID: 34333380
[TBL] [Abstract][Full Text] [Related]
29. Re-emergence of a tumefactive demyelinating lesion after initiation of fingolimod therapy.
Hashimoto Y; Shinoda K; Tanaka E; Uehara T; Matsushita T; Yamasaki R; Kira JI
J Neurol Sci; 2017 Aug; 379():167-168. PubMed ID: 28716234
[No Abstract] [Full Text] [Related]
30. Conventional and advanced magnetic resonance imaging in tumefactive demyelination.
Saini J; Chatterjee S; Thomas B; Kesavadas C
Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739
[TBL] [Abstract][Full Text] [Related]
31. Tumefactive demyelination: an approach to diagnosis and management.
Hardy TA; Chataway J
J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):1047-53. PubMed ID: 23334629
[TBL] [Abstract][Full Text] [Related]
32. Clinical and magnetic resonance imaging (MRI) distinctions between tumefactive demyelination and brain tumors in children.
Yiu EM; Laughlin S; Verhey LH; Banwell BL;
J Child Neurol; 2014 May; 29(5):654-65. PubMed ID: 24092896
[TBL] [Abstract][Full Text] [Related]
33. Value of 18F-FET PET in Patients With Suspected Tumefactive Demyelinating Disease-Preliminary Experience From a Retrospective Analysis.
Barbagallo M; Albatly AA; Schreiner S; Hayward-Könnecke HK; Buck A; Kollias SS; Huellner MW
Clin Nucl Med; 2018 Nov; 43(11):e385-e391. PubMed ID: 30153143
[TBL] [Abstract][Full Text] [Related]
34. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
Balloy G; Pelletier J; Suchet L; Lebrun C; Cohen M; Vermersch P; Zephir H; Duhin E; Gout O; Deschamps R; Le Page E; Edan G; Labauge P; Carra-Dallieres C; Rumbach L; Berger E; Lejeune P; Devos P; N'Kendjuo JB; Coustans M; Auffray-Calvier E; Daumas-Duport B; Michel L; Lefrere F; Laplaud DA; Brosset C; Derkinderen P; de Seze J; Wiertlewski S;
J Neurol; 2018 Oct; 265(10):2251-2259. PubMed ID: 30054790
[TBL] [Abstract][Full Text] [Related]
35. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
36. Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
Frederick MC; Cameron MH
Curr Neurol Neurosci Rep; 2016 Mar; 16(3):26. PubMed ID: 26847090
[TBL] [Abstract][Full Text] [Related]
37. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH
Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924
[TBL] [Abstract][Full Text] [Related]
38. [Clinical, radiographic, prognostic and therapeutic aspects of demelinating disease with tumefactive demyelinating lesions].
Launay M; Lebrun C; Giordana E; Chanalet S; Thomas P
Rev Neurol (Paris); 2011 Jan; 167(1):14-22. PubMed ID: 20739040
[TBL] [Abstract][Full Text] [Related]
39. Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review.
Rahn AC; Köpke S; Stellmann JP; Schiffmann I; Lukas C; Chard D; Heesen C
Acta Neurol Scand; 2019 Jan; 139(1):18-32. PubMed ID: 30091223
[TBL] [Abstract][Full Text] [Related]
40. Tumefactive multiple sclerosis (TMS): A case series of this challenging variant of MS.
Villarreal JV; Abraham MJ; Acevedo JAG; Rai PK; Thottempudi N; Fang X; Gogia B
Mult Scler Relat Disord; 2021 Feb; 48():102699. PubMed ID: 33373797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
